Paiimbestigahan din ni Senate Minority Leader Franklin M. Drilon ang tax record at tax liabilities ng Pharmally Pharmaceutical Corp., ang kompanyang nakakuha ng halos P10 bilyong government contract mula sa Procurement Service- Department of Budget and Management na pinamunuan ni dating Undersecretary Lloyd Christopher Lao.

“From what has been shown, it is not clear that Pharmally has paid the correct taxes. Bayanihan 1 and 2 does not exempt from VAT local purchases, therefore, the amount paid to Pharmally should have been subject to a 2% withholding tax on government payments, and a 5% VAT withholding,” sabi ni Drilon sa isang statement.

“Furthermore, the sale of the PPE to government is subject to an output VAT of 12% because the product they imported are exempt therefore, they would not have any input VAT to deduct except for the 5% VAT withheld if this was properly withheld from the payment to Pharmally by PS-DBM,” dagdag nito.

Bukod sa usapin ng overpricing, sinabi ni Drilon na maaaring may nilabag din sa tax laws ang Pharmally.

“Apart from the issue of overpricing, there could be violations of our tax laws by Pharmally. We should examine the potential tax liabilities of this dubious trading firm. Did Pharmally pay any percentage tax? Did it pay any excise tax and documentary stamp tax payments?” diin ni Drilon.

Batay sa mga record, ang Pharmally ay kabilang sa domestic corporation na subject sa probisyon ng Section 27 ng Tax Code.

Sabi ni Drilon, para makasali ang isang kompanya sa mga government bidding, kailangan kumuha ang mga kompanya na tax clearance mula sa Bureau of Internal Revenue.

Subalit giit ng senador, may mga ulat na walang record ang Pharmally na kumuha ito ng tax clearance kaya’t dapat lang na sumailalim ito sa tax audit ng BIR.

“The BIR should review possible violations of the tax laws committed by this dubious and shadowy company that bagged billions of pesos in government contracts. They should zero in on potential tax crimes and tax fraud by Pharmally,” ayon kay Drilon.

Sabi ni Drilon na misteryoso at kwestiyonable kung paano nakakakuha ang Pharmally ng P7 bilyon para pondohan ang kanilang inventory supply.

Batay sa financial statement, ang Pharmally ay may P7,485,401,046 sales at P7,092274,180 cost of sales. Ini-report din nito na ang kanilang cost of inventory ay P7 bilyon habang ang liability ay P1,748,879 lamang.

“Where did it get the P7 billion to buy their inventory of supplies with only P625,000 paid up capital? How did they acquire the inventory?” tanong ni Drilon. “There is none on record that will show a payable or equity close to P7 billion. It remains a mystery.”

“There is no indication where the P7 billion came from. Without any explanation, it appears that it just fell into its lap. Pharmally executives should come out and explain this among other things,” dagdag pa pa nito.

Sa paid-up capital ng P625,000 lamang, nakapagtala ang Pharmally ng gross income na P384.04 milyon at net income ng P264.65 milyon noong 2020 mula sa zero income noong 2019.

Nauna nang hinikayat ni Drilon ang mga opisyal ng Senado na humarap sa Senado at tumestigo tungkol sa P10 bilyong supply deal na nakuha nila sa PS-DBM

“Kung wala kang itinatago, bakit ka magtatago? Where are the officials of Pharmally?”, sabi pa ni Drilon.

The post Pharmally hindi nagbayad ng tamang buwis – Drilon first appeared on Abante TNT Breaking News.

Source: Abante (https://tnt.abante.com.ph/pharmally-hindi-nagbayad-ng-tamang-buwis-drilon/?utm_source=rss&utm_medium=rss&utm_campaign=pharmally-hindi-nagbayad-ng-tamang-buwis-drilon)